Clinical trials: CGA

Prostate Cancer

Study of Lanreotide in Non Metastatic Castration-resistant Prostate Cancer Patients

• Terminated
• Age: 18 years and older
• Phase 3
• Results posted

The aim of the study is to compare in an exploratory fashion the efficacy on progression-free survival of lanreotide in addition to non steroidal anti androgens and LHRH-a in non metastatic castrate resistant prostate cancer…

Trial name

POSEIDON (NCT01313273)

Testing

Lanreotide, non steroidal anti androgens and LHRH-a, Non steroidal anti androgens and LHRH-a

Where

Italy

Volunteers

3 people

Sponsor

Ipsen